Peter Clark’s scientific contributions

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (1)


Figure 1 Immunohistochemistry images. A: Esophageal adenocarcinoma (EAC) demonstrating diffuse, heterogeneous and mosaic-type expression for NY-ESO-1 (immunohistochemistry, IHC × 10); B: EAC showing a diffuse and granular pattern of cytoplasmic NY-ESO-1 expression (IHC × 40); C: Esophageal submucosal gland demonstrating dot-type expression for NY-ESO-1 (IHC × 60); D: Barrett's esophagus of intestinal-type showing apical cytoplasmic dot-type expression for NY-ESO-1 (IHC × 60); E: EAC showing nuclear dot-type expression for NY-ESO-1 (IHC × 60); F: Well differentiated EAC with apical cytoplasmic dot-type expression for NY-ESO-1 (IHC × 60); G: Positive control (testis) demonstrating diffuse NY-ESO-1 expression which is restricted to primitive germ cells (IHC × 20); H: Negative control (colon) with dot-type pattern at nuclear, paranuclear and cytoplasmic locations, involving a basal crypt. Two of the cytoplasmic dots show alignment and apparent relationship to the paranuclear dot (IHC × 60).
Immunohistochemical assessment of NY-ESO-1 expression in esophageal adenocarcinoma resection specimens
  • Article
  • Full-text available

April 2014

·

67 Reads

·

6 Citations

World Journal of Gastroenterology

Stephen J Hayes

·

·

Peter Clark

·

[...]

·

To assess NY-ESO-1 expression in a cohort of esophageal adenocarcinomas. A retrospective search of our tissue archive for esophageal resection specimens containing esophageal adenocarcinoma was performed, for cases which had previously been reported for diagnostic purposes, using the systematised nomenclature of human and veterinary medicine coding system. Original haematoxylin and eosin stained sections were reviewed, using light microscopy, to confirm classification and tumour differentiation. A total of 27 adenocarcinoma resection specimens were then assessed using immunohistochemistry for NY-ESO-1 expression: 4 well differentiated, 14 moderately differentiated, 4 moderate-poorly differentiated, and 5 poorly differentiated. Four out of a total of 27 cases of esophageal adenocarcinoma examined (15%) displayed diffuse cytoplasmic and nuclear expression for NY-ESO-1. They displayed a heterogeneous and mosaic-type pattern of diffuse staining. Diffuse cytoplasmic staining was not identified in any of these structures: stroma, normal squamous epithelium, normal submucosal gland and duct, Barrett's esophagus (goblet cell), Barrett's esophagus (non-goblet cell) and high grade glandular dysplasia. All adenocarcinomas showed an unexpected dot-type pattern of staining at nuclear, paranuclear and cytoplasmic locations. Similar dot-type staining, with varying frequency and size of dots, was observed on examination of Barrett's metaplasia, esophageal submucosal gland acini and the large bowel negative control, predominantly at the crypt base. Furthermore, a prominent pattern of apical (luminal) cytoplasmic dot-type staining was observed in some cases of Barrett's metaplasia and also adenocarcinoma. A further morphological finding of interest was noted on examination of haematoxylin and eosin stained sections, as aggregates of lymphocytes were consistently noted to surround submucosal glands. We have demonstrated for the first time NY-ESO-1 expression by esophageal adenocarcinomas, Barrett's metaplasia and normal tissues other than germ cells.

Download

Citations (1)


... Although, NY-ESO-1 antigen is always localized in the cytoplasm, some limited studies have also reported simultaneous expression of NY-ESO-1 in both nucleus and cytoplasm of tumor tissues. It is unclear if this simultaneous expression, observed in certain cancers, is a stable trait or varies over time [26][27][28]. ...

Reference:

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
Immunohistochemical assessment of NY-ESO-1 expression in esophageal adenocarcinoma resection specimens

World Journal of Gastroenterology